8.50
+0.08(+0.95%)
Currency In USD
| Previous Close | 8.42 |
| Open | 8.73 |
| Day High | 8.86 |
| Day Low | 8.24 |
| 52-Week High | 20.63 |
| 52-Week Low | 1.8 |
| Volume | 284,461 |
| Average Volume | 404,373 |
| Market Cap | 73.97M |
| PE | -3.92 |
| EPS | -2.17 |
| Moving Average 50 Days | 7.45 |
| Moving Average 200 Days | 7.22 |
| Change | 0.08 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.05 as of July 30, 2025 at a share price of $8.53. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $95.57 as of July 30, 2025 at a share price of $8.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
GlobeNewswire Inc.
Jul 28, 2025 11:00 AM GMT
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduct
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOS
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
GlobeNewswire Inc.
Jul 08, 2025 11:00 AM GMT
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in